^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    carfilzomib

    i
    Other names: PR-171, ONO 7057, ONO-7057, ONO7057, PR171, PR 171
    Company:
    Generic mfg.
    Drug class:
    Proteasome inhibitor
    Related drugs:
    2d
    Proteasomal inhibition compromises microvascular integrity via distinct effects on non-immune endothelial cells and immune cells. (PubMed, Front Immunol)
    This indicates that although proteasomal inhibition is not inflammatory, TNF present in the microvascular environment synergizes with the drugs to compromise endothelial function. Our observations provide an explanation for how microvascular damage potentially underlies tissue injury driven by Bortezomib or Carfilzomib.
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • CASP3 (Caspase 3) • CASP8 (Caspase 8) • CASP9 (Caspase 9)
    |
    bortezomib • carfilzomib
    2d
    KTX-MMSET-001: A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=165, Recruiting, K36 Therapeutics, Inc. | N=125 --> 165
    Enrollment change
    |
    carfilzomib • dexamethasone • pomalidomide • mezigdomide (CC-92480) • gintemetostat (KTX-1001)
    5d
    A Study of Daratumumab (clinicaltrials.gov)
    P3, N=500, Recruiting, Janssen Research & Development, LLC | Trial completion date: Jan 2029 --> Dec 2029
    Trial completion date
    |
    lenalidomide • Darzalex (daratumumab) • carfilzomib • pomalidomide • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • dexamethasone injection
    7d
    SKylaRk: KRDI in Transplant-Eligible MM (clinicaltrials.gov)
    P2, N=50, Active, not recruiting, Massachusetts General Hospital | Trial completion date: Mar 2026 --> Dec 2026
    Trial completion date
    |
    lenalidomide • carfilzomib • Sarclisa (isatuximab-irfc)
    7d
    D8311C00001: A trial to learn how well AZD0120 works and how safe it is in people with relapsed or refractory multiple myeloma. (2025-523285-25-00)
    P2/3, N=153, Not yet recruiting, AstraZeneca AB | N=38 --> 153
    Enrollment change
    |
    bortezomib • Darzalex (daratumumab) • carfilzomib • pomalidomide • AZD0120
    9d
    COMMANDER: COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide (clinicaltrials.gov)
    P1/2, N=80, Active, not recruiting, University of Alabama at Birmingham | Trial completion date: Oct 2026 --> Aug 2028 | Trial primary completion date: Apr 2026 --> Aug 2028
    Trial completion date • Trial primary completion date • Minimal residual disease
    |
    clonoSEQ®
    |
    Darzalex (daratumumab) • carfilzomib • dexamethasone • iberdomide (CC-220)
    13d
    Real-World Patterns of Utilization of Lenalidomide-based Triplet Regimens in FIrst RElapsed Multiple Myeloma Patients: Evidence From Medical Record Review (clinicaltrials.gov)
    P=N/A, N=100, Completed, Fondazione IRCCS Policlinico San Matteo di Pavia
    New trial • Real-world evidence
    |
    lenalidomide • carfilzomib
    14d
    CEVOLUTION: Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma (clinicaltrials.gov)
    P3, N=380, Recruiting, Hoffmann-La Roche | Not yet recruiting --> Recruiting | Trial primary completion date: Jun 2029 --> Oct 2028
    Enrollment open • Trial primary completion date
    |
    carfilzomib • dexamethasone • pomalidomide • Empliciti (elotuzumab) • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • cevostamab (RG6160)
    14d
    CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=36, Active, not recruiting, National Cancer Institute (NCI) | Terminated --> Active, not recruiting | N=19 --> 36 | Trial completion date: Nov 2023 --> Sep 2026 | Trial primary completion date: Nov 2023 --> Sep 2026
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    carfilzomib • telaglenastat (CB-839) • Hemady (dexamethasone tablets)
    14d
    Design, radiolabeling, and biological evaluation of a novel 177Lu-AAZTA5-Carfilzomib conjugate as a proteasome-targeted theranostic agent for multiple myeloma. (PubMed, J Pharm Sci)
    Biodistribution studies in Ehrlich tumor-bearing mice showed significant tumor uptake (6.8 %ID/g at 2 h p.i.) with rapid clearance from blood and normal tissues. These findings highlight the potential of 177Lu-AAZTA5-Carfilzomib as a promising proteasome-targeted theranostic candidate for multiple myeloma.
    Journal
    |
    B2M (Beta-2-microglobulin)
    |
    carfilzomib
    14d
    EMN24: A Clinical trial to compare the combination of Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone versus the combination of Carfilzomib-Lenalidomide-Dexamethasone in newly diagnosed multiple myeloma patients eligible for autologous stem cell transplantation (IsKia TRIAL) (2024-513422-38-00)
    P2/3, N=302, Active, not recruiting, European Myeloma Network B.V., Emn Trial Office S.r.l. Impresa Sociale | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    lenalidomide • carfilzomib • dexamethasone • Sarclisa (isatuximab-irfc)
    15d
    Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial (clinicaltrials.gov)
    P2, N=74, Not yet recruiting, National Cancer Institute (NCI)
    New P2 trial
    |
    lenalidomide • carfilzomib • melphalan • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Tecvayli (teclistamab-cqyv) • Hemady (dexamethasone tablets) • plerixafor